Skip to content

Research on the verification of tumor targeting and therapeutic effects of supramolecular assemblies-based nanomaterials

Supramolecular assembly-based nanofluorescent probes for precise and stable imaging of tumors

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500101687
Enrollment
Unknown
Registered
2025-04-28
Start date
2026-01-08
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder cancer

Interventions

Gold Standard:Cystoscopy combined with urine exfoliation cytology
Index test:Near-infrared peptide molecule probe. The equipment models are as follows: 28164 AC, 28164 BC, 28164 FC
The camera host equipment model is as follows: GCYJ-F04M-090002
The model of cold light source equipment is as follows: GCYJ-F23G-090004.

Sponsors

Harbin Medical University Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Be older than 18 years of age; 2. Diagnosed with bladder tumor and met the surgical indications for radical cystectomy and other related procedures; 3. No prior systemic therapy or radiotherapy; 4. No active infectious diseases (tuberculosis, HIV, hepatitis, syphilis, etc.).

Exclusion criteria

Exclusion criteria: 1. Have had other malignant tumors; 2. Presence of any active autoimmune disease; 3. pregnant women and children; 4. Those who have used systemic therapeutic dose steroid drugs (except for those who have recently or currently used inhaled steroids) or other immunotherapy (such as interleukin, interferon, thymosin, etc.) within 2 weeks before specimen collection.

Design outcomes

Primary

MeasureTime frame
Fluorescence intensity of bladder tumor;Accuracy ;

Secondary

MeasureTime frame
Sensitivity ;Specificity ;Positive predicative value;

Countries

China

Contacts

Public ContactDayong Hou

Harbin Medical University Cancer Hospital

1301385343@qq.com+86 132 0460 6071

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026